Salubris SAL0137 drug clinical trial application accepted

Zhitong
2025.10.15 09:33
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Salubris announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the innovative small molecule drug SAL0137 (project code: SAL0137) developed by the company has been accepted. SAL0137 is an oral small molecule drug developed by the company with independent intellectual property rights. The application submitted by the company is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein (a)

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0137 (project code: SAL0137) has been accepted. SAL0137 is an orally administered small molecule drug developed by the company with independent intellectual property rights. The application submitted by the company is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein(a)

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer